Astra sinks Advent's USD 7.6bn buyout of biotech Sobi

Astrazeneca was the reason that the acquisition of Swedish pharmaceutical firm Sobi failed, as the pharmaceutical giant itself wanted certain assets from the Swedish company, sources say.
By Dinesh Nair and Thomas Mulier, bloomberg

Astrazeneca Plc effectively blocked a USD 7.6bn takeover of Swedish Orphan Biovitrum AB by withholding its 8 percent stake in the drugmaker from a buyout offer by Advent International and Singapore wealth fund GIC, according to people familiar with the situation.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading